



CLINICAL SUMMARY

Cardiac erosions associated with
septal defect closure devices

Cardiac erosion: A potentially fatal complication associated with septal defect closure devices¹⁻¹³

Transcatheter closure of **Patent Foramen Ovale (PFO)** and **Atrial Septal Defects (ASDs)** is generally recognized as a safe and effective procedure.^{1,14}

Cardiac erosions may require emergent open surgical intervention and pose a potential risk of death.^{1-13,15}

Cardiac erosion of a septal device through the atrial wall or pericardial space² may result in pericardial effusion, cardiac tamponade or death.^{1-13,15}

Cardiac erosions

have been reported for both ASD and PFO devices.^{1-13,15}

Specific mechanisms and risk factors for cardiac erosion are likely to be multifactorial^{2,4,6,7,15}

Mechanical risk factors

- Occluder type – potential stiffness of device
- Device movement within the heart – motion of relatively stiff occluder device against adjacent cardiac structures

Patient risk factors

- Patient age
- Absent/Deficient rims (Anterior and/or superior)
- Incorrect device sizing (Over sizing or under sizing)

Cardiac erosions have been reported up to 12 years after implantation¹⁰

EARLY AFTER
IMPLANTATION^{1-8,11,12,13,15}



6 YEARS^{9,13}



12 YEARS¹⁰



Cardiac erosions reported for septal defect closure devices

Commercially available devices with reported **cardiac erosions**^{1-13,15}:

Device	Manufacturer
ABBOTT® AMPLATZER Septal Occluder ^{1-8,10,12,13,15}	Abbott Medical
ABBOTT® AMPLATZER PFO Occluder ^{9,11,12}	Abbott Medical
ABBOTT® AMPLATZER Multifenestrated Occluder – “Cribriform” ¹²	Abbott Medical

GORE® CARDIOFORM Occluders have no reported history of cardiac erosion^{*,†}

GORE® CARDIOFORM Septal Occluder[‡]

GORE® CARDIOFORM ASD Occluder[§]

0

reported cardiac erosions^{*}

11+ years

of clinical use
beginning in June 2011

68,000+

devices sold globally



0

reported cardiac erosions[†]

7+ years

of clinical use beginning
in February 2015

8,000+

devices sold globally

* Data on file. July 2011–January 2023; W. L. Gore & Associates, Inc.; Flagstaff, AZ.

† Data on file. March 2015–January 2023; W. L. Gore & Associates, Inc.; Flagstaff, AZ.

‡ Clinical experience has reported three cases of clinical sequelae associated with wire frame fracture for GORE® CARDIOFORM Septal Occluder^{*,16} from a total of > 68,000 devices sold globally (correlating to a reported incidence rate of 0.004%). In two of these cases, it was reported that both patients suffered from pericardial tamponade due to perforation of the atrial wall induced by device wire frame fracture.¹⁶ In the third case it was reported that device wire frame fracture was a likely cause for the formation of a fistula between the left atrium and aorta.[†] It was also reported that urgent medical care surgical reintervention was required with all three patients making a full recovery.^{*,16}

§ Since first clinical use in February 2015, there have been no reported incidents of clinical sequelae associated with wire frame fracture for GORE® CARDIOFORM ASD Occluder from a total of > 8,000 devices sold globally.[†]

ABBOTT and AMPLATZER are trademarks of Abbott Laboratories.

Cardiac erosions reported in literature for ABBOTT® AMPLATZER Occluders:

ABBOTT® AMPLATZER Septal Occluder

Reported between 2002 and 2014²

125 erosions

9 deaths

7.2%

mortality rate
for patients with
reported erosions

ABBOTT® AMPLATZER Septal Occluder, ABBOTT® AMPLATZER PFO Occluder and ABBOTT® AMPLATZER Multifenestrated Septal Occluder – “Cribriform”

Reported between 2012 and 2018¹⁷

90 erosions

4 deaths

4.4%

mortality rate
for patients with
reported erosions

ABBOTT® AMPLATZER Septal Occluder

Reported in a prospective, multicenter, post-approval study⁸

3 erosions

0.3% reported incidence rate

Estimates for cardiac erosion following ABBOTT® AMPLATZER Septal Occluder implantation reported to range from 0.1–0.3%.¹³

ABBOTT® AMPLATZER PFO Occluder

Reported in the AGA Registry between October 2000 and December 2006¹¹

2 erosions

0.018% reported incidence rate

Cardiac erosion incidence rate of 0.018% reported for ABBOTT® AMPLATZER PFO Occluder.¹¹


Cardiac erosion: A potential risk for ASD patients with deficient retro-aortic rims

ABBOTT® AMPLATZER Septal Occluder – *Instructions for Use* (IFU)

2012 modification to IFU included a warning statement that patients with a retro-aortic rim of less than 5 mm in any echocardiographic plane may be at risk of erosion.^{2,17,18}

IFU warnings, potential adverse events and precautions related to cardiac erosion:

Device	Related IFU Content
ABBOTT® AMPLATZER Septal Occluder	<p>Warning: Patients with a retro-aortic rim of less than 5 mm in any echocardiographic plane, or patients in whom the device physically impinges on (i.e., indents or distorts) the aortic root, may be at increased risk of erosion.¹⁸</p> <p>Potential adverse event: tissue erosion.¹⁸</p>
ABBOTT® AMPLATZER PFO Occluder	<p>Potential adverse event: device erosion.¹⁹</p>
ABBOTT® AMPLATZER Multifenestrated Septal Occluder – “Cribriform”	<p>Patient selection: Certain patients may be at higher risk for complications such as tissue erosion and device embolization. If higher risk patients have devices implanted, closer follow-up is warranted. Higher risk patients include the following:</p> <ul style="list-style-type: none"> ▪ Patients with deformation of the device at the aortic root ▪ Patients with high defects (Minimal aortic and superior rims) ▪ Patients with less than a 9 mm distance from the central defect to the aortic root or superior vena cava orifice²⁰ <p>Potential adverse event: erosion²⁰</p>
GORE® CARDIOFORM Septal Occluder	<p>No warnings, potential adverse events or precautions related to cardiac erosions or use in patients with deficient retro-aortic rims.²¹</p>
GORE® CARDIOFORM ASD Occluder	<p>No warnings, potential adverse events or precautions related to cardiac erosions or use in patients with deficient retro-aortic rims.²²</p>



60% of patients

undergoing transcatheter ASD closure have been reported to have deficient retro-aortic rims^{*,23}

In the Gore ASSURED Clinical Study, 57% of patients had a deficient retro-aortic rim and were treated with the GORE® CARDIOFORM ASD Occluder.^{*,24}

For more information on GORE® CARDIOFORM Occluders, contact your Field Sales Associate.

* Deficient retro-aortic rim was defined as a retro-aortic rim measuring less than or equal to 5 mm on any view on echocardiogram.²³

ABBOTT and AMPLATZER are trademarks of Abbott Laboratories.

References

1. Moore J, Hegde S, El-Said H, et al; ACC IMPACT Steering Committee. Transcatheter device closure of atrial septal defects: a safety review. *JACC: Cardiovascular Interventions* 2013;6(5):433-442.
2. McElhinney DB, Quartermain MD, Kenny D, Alboliras E, Amin Z. Relative risk factors for cardiac erosion following transcatheter closure of atrial septal defects: a case-control study. *Circulation* 2016;133(18):1738-1746.
3. DiBardino DJ, McElhinney DB, Kaza AK, Mayer JE Jr. Analysis of the US Food and Drug Administration Manufacturer and User Facility Device Experience database for adverse events involving Amplatzer septal occluder devices and comparison with the Society of Thoracic Surgery congenital cardiac surgery database. *Journal of Thoracic & Cardiovascular Surgery* 2009;137(6):1334-1341.
4. Thomson JDR, Qureshi SA. Device closure of secundum atrial septal defect's and the risk of cardiac erosion. *Echo Research & Practice* 2015;2(4):R73-R78.
5. Delaney JW, Li JS, Rhodes JF. Major complications associated with transcatheter atrial septal occluder implantation: a review of the medical literature and the manufacturer and user facility device experience (MAUDE) database. *Congenital Heart Disease* 2007;2(4):256-264.
6. El-Said HG, Moore JW. Erosion by the Amplatzer septal occluder: experienced operator opinions at odds with manufacturer recommendations? *Catheterization & Cardiovascular Interventions* 2009;73(7):925-930.
7. Kitano M, Yazaki S, Sugiyama H, Ohtsuki S, Tomita H. Risk factors and predictors of cardiac erosion discovered from 12 Japanese patients who developed erosion after atrial septal defect closure using Amplatzer septal occluder. *Pediatric Cardiology* 2020;41(2):297-308.
8. Turner DR, Owada CY, Sang CJ Jr, Khan M, Lim DS. Closure of secundum atrial septal defects with the AMPLATZER Septal Occluder: a prospective, multicenter, post-approval study. *Circulation: Cardiovascular Interventions* 2017;10(8):e004212.
9. Taggart NW, Dearani JA, Hagler DJ. Late erosion of an Amplatzer septal occluder device 6 years after placement. *Journal of Thoracic & Cardiovascular Surgery* 2011;142(1):221-222.
10. Bergonti M, Toscano O, Teruzzi G, Trabattoni D. Never drop your guard down after atrial septal defect closure: a case report. *European Heart Journal - Case Reports* 2019;3(2):ytz094.
11. Amin Z, Hijazi ZM, Bass JL, Cheatham JP, Hellenbrand W, Kleinman CS. PFO closure complications from the AGA Registry. *Catheterization & Cardiovascular Interventions* 2008;72(1):74-79.
12. Bier ML, Dhawan P, Shah SU, et al. Cardiac erosions with the Amplatzer Septal Occluder: adverse events in the Manufacturer and User Facility Device Experience (MAUDE) Database since the 2012 FDA review. *Structural Heart* 2021;5(1):85-89. <https://www.sciencedirect.com/science/article/pii/S2474870622007734>
13. Crawford GB, Brindis RG, Krucoff MW, Mansalis BP, Carroll JD. Percutaneous atrial septal occluder devices and cardiac erosion: a review of the literature. *Catheterization & Cardiovascular Interventions* 2012;80(2):157-167.
14. Varotto L, Bregolin G, Paccanaro M, De Boni A, Bonanno C, Perini F. The closure of patent foramen ovale in preventing subsequent neurological events: a Bayesian network meta-analysis to identify the best device. *Cerebrovascular Diseases* 2020;49(2):124-134.
15. Amin Z, Hijazi ZM, Bass JL, et al. Erosion of Amplatzer Septal Occluder Device After Closure of Secundum Atrial Septal Defects: Review of Registry of Complications and Recommendations to Minimize Future Risk. *Catheterization & Cardiovascular Interventions* 2004;63:496-502.
16. Kumar P, Orford JL, Tobis JM. Two cases of pericardial tamponade due to nitinol wire fracture of a Gore Septal Occluder. *Catheterization & Cardiovascular Interventions* 2020;96(1):219-224.
17. Mallula K, Amin Z. Recent changes in instructions for use for the Amplatzer atrial septal defect occluder: how to incorporate these changes while using transesophageal echocardiography or intracardiac echocardiography? *Pediatric Cardiology* 2012;33(7):995-1000.
18. AMPLATZER™ Septal Occluder [Instructions for Use]. Plymouth, MN: Abbott Medical; 2022. ARTEN600196097 B.
19. AMPLATZER™ PFO Occluder [Instructions for Use]. Plymouth, MN: Abbott Medical; 2022. ARTEN600197057 B.
20. AMPLATZER™ Multifenestrated Septal Occluder – “Cribriform” [Instructions for Use]. Plymouth, MN: Abbott Medical; 2022. ARTEN600196098 B.
21. GORE® CARDIOFORM Septal Occluder [Instructions for Use]. Flagstaff, AZ: W. L. Gore & Associates, Inc; 2021. MD184733.
22. GORE® CARDIOFORM ASD Occluder [Instructions for Use]. Flagstaff, AZ: W. L. Gore & Associates, Inc; 2023. MD190349.
23. O'Byrne ML, Glatz AC, Sunderji S, et al. Prevalence of deficient retro-aortic rim and its effects on outcomes in device closure of atrial septal defects. *Pediatric Cardiology* 2014;35(7):1181-1190.
24. Sommer RJ, Love BA, Paolillo JA, et al; ASSURED Investigators. ASSURED clinical study: new GORE® CARDIOFORM ASD Occluder for transcatheter closure of atrial septal defect. *Catheterization & Cardiovascular Interventions* 2020;95(7):1285-1295.

 Consult Instructions
for Use
eifu.goremedical.com

INDICATIONS FOR USE IN THE U.S.: The GORE® CARDIOFORM Septal Occluder is a permanently implanted device indicated for the percutaneous, transcatheter closure of the following defects of the atrial septum: ostium secundum atrial septal defects (ASDs); patent foramen ovale (PFO) to reduce the risk of recurrent ischemic stroke in patients, predominantly between the ages of 18 and 60 years, who have had a cryptogenic stroke due to a presumed paradoxical embolism, as determined by a neurologist and cardiologist following an evaluation to exclude known causes of ischemic stroke. **CONTRAINDICATIONS:** The GORE® CARDIOFORM Septal Occluder is contraindicated for use in patients: unable to take antiplatelet or anticoagulant medications such as aspirin, heparin or warfarin; with anatomy where the GORE® CARDIOFORM Septal Occluder size or position would interfere with other intracardiac or intravascular structures, such as cardiac valves or pulmonary veins; with active endocarditis, or other infections producing bacteremia, or patients with known sepsis within one month of planned implantation, or any other infection that cannot be treated successfully prior to device placement; with known intracardiac thrombi.

INDICATIONS FOR USE IN THE U.S.: The GORE® CARDIOFORM ASD Occluder is a permanently implanted device indicated for the percutaneous, transcatheter closure of ostium secundum atrial septal defects (ASDs). **CONTRAINDICATIONS:** The GORE® CARDIOFORM ASD Occluder is contraindicated for use in patients: Unable to take anti-platelet or anticoagulant medications such as aspirin, heparin or warfarin; with anatomy where the GORE® CARDIOFORM ASD Occluder size or position would interfere with other intracardiac or intravascular structures, such as cardiac valves or pulmonary veins; with active endocarditis, or other infections producing bacteremia, or patients with known sepsis within one month of planned implantation, or any other infection that cannot be treated successfully prior to device placement; with known intracardiac thrombi.

Refer to *Instructions for Use* at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. Rx Only

Products listed may not be available in all markets.

In some jurisdictions, ASPIRIN is a trademark of Bayer Intellectual Property GmbH or its affiliated companies.

ABBOTT and AMPLATZER are trademarks of Abbott Laboratories.

GORE, *Together, improving life*, CARDIOFORM and designs are trademarks of W. L. Gore & Associates.

© 2023 W. L. Gore & Associates, Inc. 22524001-EN JULY 2023

W. L. Gore & Associates, Inc.
goremedical.com

Asia Pacific +65 67332882 **Australia/New Zealand** 1800 680 424 **Europe** 00800 6334 4673
United States Flagstaff, AZ 86004 800 437 8181 928 779 2771

